Eltrombopag, a thrombopoietin receptor agonist, may increase platelet is important throughout thrombocytopenic people. We performed a new stage Two examine, adaptively randomizing patients with ≥35 days post-HSCT for placebo as well as eltrombopag in a platelet depend ≤20,000/µL regarding 1 week as well as platelet transfusion-dependent plus a ne…[Read more]